Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer

Phase 2

Terminated

• Conditions: Invasive Breast Cancer
• Interventions: Other: Placebo; Drug: Vandetanib

• Registration Number: NCT01934335
• Lead Sponsor: Ronald Weigel

Brief Summary

The purpose of this project is to examine whether treatment with vandetanib has an effect on the tumor cells in breast cancer by examining tissue markers.

Detailed Description

The purpose of this research study is to test whether vandetanib has an effect on tumor growth markers. Vandetanib is not approved by the FDA for use in treating breast cancer. This study will compare vandetanib to a placebo.

The proposed study is designed to determine the change in Ki-67 expression on paired breast cancer samples obtained before and after treatment with vandetanib. Other tumor markers including RET, TUNEL and phosphorylation specific levels of ERK1/2, AKT and mTOR will also be assessed on the paired samples.

Those who have a core biopsy of the breast which demonstrates invasive breast cancer and requires surgical excision of the lesion will be eligible for inclusion in the study. The tyrosine kinase inhibitor, vandetanib 300 mg, will be given once a day for 7-14 days prior to surgery. Following surgery, tissue markers would be analyzed on each of the paired samples, allowing for rapid assessment of in vivo response to TKI treatment.

Study Timeline

• Study First Submitted: 2013-08-29
• Study First Submitted QC: 2013-08-29
• Study First Posted: 2013-09-04
• Study Start: 2013-10
• Primary Completion: 2018-12-21
• Study Completion: 2018-12-21
• Results First Submitted: 2021-05-13
• Status Verified: 2021-10
• Results First Submitted QC: 2021-10-01
• Last Update Submitted: 2021-10-01
• Results First Posted: 2021-11-01
• Last Update Posted: 2021-11-01

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Female
• Target Recruitment: 12

Inclusion Criteria

• Patients with core breast biopsy that, on pathology review, demonstrates invasive breast cancer and are determined to need surgical excision of the lesion. All subtypes of invasive breast cancer will be enrolled. Core biopsy specimens of enrolled patients will be stained for RET by immunohistochemistry and scored, however, patients will not be excluded according to RET expression.
• Female gender
• Age >/= 18 years of age
• ECOG performance status </= 2
• Life expectancy of greater than 6 months
• Ability and willingness to provide informed consent to participate in study

Read More

Exclusion Criteria

• Prolonged QT interval (QTc > 480 milliseconds) on screening EKG or congenital long QT syndrome
• Any concomitant medications that are known to be associated with Torsades de Pointes or QT elongation (see appendix 2).
• Hypertension not controlled by medical therapy (systolic BP greater than 160 millimeters of mercury [mmHg] or diastolic blood pressure great than 100 mmHg).
• Patients taking metformin or digoxin.
• History of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (CTCAE Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Patients with atrial fibrillation controlled by medication are permitted.
• Significant cardiac event (e.g., myocardial infarction), superior vena cava syndrome, New York Heart Association (NYHA) classification of heart disease ≥2 within 12 weeks, or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia.
• Serum calcium or magnesium outside the institutional range of normal.
• Serum Potassium < 4.0 mmol/L or above 5.0 mmol/L
• Creatinine clearance < 50 ml/min
• PT > 12 seconds or PTT > 31 seconds
• Platelet count of < 100,000
• Serum bilirubin greater than 1.5 mg/dl
• Alanine aminotransferase (ALT) > 50 U/L, aspartate aminotransferase (AST) > 65 U/L, or alkaline phosphatase (ALP) > 250 U/L
• Any cytotoxic treatments, such as neoadjuvant chemotherapy, planned before subsequent surgical procedure.
• Previous exposure to Vandetanib
• Previous enrollment or randomization in this study
• Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and staff at UIHC).
• Previous or current malignancies of other histologies within the last 5 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin.
• Patients who have received prior surgical site radiation.
• Patients on CYP3A4 inhibitors or inducers (see appendix 1).
• Inability to test core biopsy for study markers
• Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing must be performed within 2 weeks prior to randomization according to institutional standards for women of childbearing potential.)

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo, PO, q day for 7-14 days prior to surgery.
Vandetanib	Vandetanib	Vandetanib, 300 mg, PO, q day for 7-14 days prior to surgery

Primary Outcome Measures

Name	Time	Method
Percent Change From Baseline in Ki-67 Cells Observed 2 Weeks Post-treatment	2 weeks	Pre- and post-treatment samples will be assessed by immunohistochemistry for positivity for Ki-67.

Secondary Outcome Measures

Name	Time	Method
Percent Change From Baseline in TUNEL Observed 2 Weeks Post-treatment	2 weeks	Pre- and post-treatment samples will be assessed by immunohistochemistry for positivity for TUNEL.

Trial Locations

Locations (1)

University of Iowa Hospitals and Clinics; 🇺🇸 Iowa City, Iowa, United States